BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

3201 related articles for article (PubMed ID: 25113753)

  • 1. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification.
    Cheson BD; Fisher RI; Barrington SF; Cavalli F; Schwartz LH; Zucca E; Lister TA; ; ; ; ; ; ; ; ; ; ; ; ; ; ;
    J Clin Oncol; 2014 Sep; 32(27):3059-68. PubMed ID: 25113753
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Tamayo P; Martín A; Díaz L; Cabrero M; García R; García-Talavera P; Caballero D
    Rev Esp Med Nucl Imagen Mol; 2017; 36(5):312-321. PubMed ID: 28483374
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Staging and response assessment in lymphomas: the new Lugano classification.
    Cheson BD
    Chin Clin Oncol; 2015 Mar; 4(1):5. PubMed ID: 25841712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imaging for diagnosis, staging and response assessment of Hodgkin lymphoma and non-Hodgkin lymphoma.
    McCarten KM; Nadel HR; Shulkin BL; Cho SY
    Pediatr Radiol; 2019 Oct; 49(11):1545-1564. PubMed ID: 31620854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The utility of FDG PET in diagnosis and follow-up of lymphoma in childhood.
    Sioka C
    Eur J Pediatr; 2013 Jun; 172(6):733-8. PubMed ID: 23559330
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New staging and response criteria for non-Hodgkin lymphoma and Hodgkin lymphoma.
    Cheson BD
    Radiol Clin North Am; 2008 Mar; 46(2):213-23, vii. PubMed ID: 18619377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Update on the use of FDG-PET/CT in malignant lymphoma].
    Terauchi T
    Rinsho Ketsueki; 2016; 57(10):2008-2012. PubMed ID: 27795508
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of whole-body [18F] fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) and conventional techniques in the staging of patients with Hodgkin and aggressive non Hodgkin lymphoma.
    Pelosi E; Pregno P; Penna D; Deandreis D; Chiappella A; Limerutti G; Vitolo U; Mancini M; Bisi G; Gallo E
    Radiol Med; 2008 Jun; 113(4):578-90. PubMed ID: 18414808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group.
    Barrington SF; Mikhaeel NG; Kostakoglu L; Meignan M; Hutchings M; Müeller SP; Schwartz LH; Zucca E; Fisher RI; Trotman J; Hoekstra OS; Hicks RJ; O'Doherty MJ; Hustinx R; Biggi A; Cheson BD
    J Clin Oncol; 2014 Sep; 32(27):3048-58. PubMed ID: 25113771
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Can fluorodeoxyglucose positron emission tomography/computed tomography avoid negative iliac crest biopsies in evaluation of marrow involvement by lymphoma at time of initial staging?
    Mittal BR; Manohar K; Malhotra P; Das R; Kashyap R; Bhattacharya A; Varma N; Varma S
    Leuk Lymphoma; 2011 Nov; 52(11):2111-6. PubMed ID: 21745169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FDG-PET in the detection of bone marrow disease in Hodgkin's disease and aggressive non-Hodgkin's lymphoma and its impact on clinical management.
    Pelosi E; Penna D; Deandreis D; Chiappella A; Skanjeti A; Vitolo U; Bisi G
    Q J Nucl Med Mol Imaging; 2008 Mar; 52(1):9-16. PubMed ID: 18235420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bone marrow disease detection with FDG-PET/CT and bone marrow biopsy during the staging of malignant lymphoma: results from a large multicentre study.
    Pelosi E; Penna D; Douroukas A; Bellò M; Amati A; Arena V; Passera R; Bisi G
    Q J Nucl Med Mol Imaging; 2011 Aug; 55(4):469-75. PubMed ID: 21150862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 2-[18F]fluoro-2-deoxyglucose positron-emission tomography in staging, response evaluation, and treatment planning of lymphomas.
    Specht L
    Semin Radiat Oncol; 2007 Jul; 17(3):190-7. PubMed ID: 17591566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic performance of 18F-2-fluoro-2-deoxy-D-glucose PET/computerized tomography in identifying bone marrow infiltration in new patients with diffuse large B-cell lymphoma and Hodgkin lymphoma.
    Kandeel AA; Hussein M; Zidan L; Younis J; Edesa W; Alsayed Y
    Nucl Med Commun; 2020 Mar; 41(3):269-279. PubMed ID: 31895758
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of clinical staging using the Lugano versus Ann Arbor classifications in Japanese patients with Hodgkin lymphoma.
    Makita S; Maruyama D; Maeshima AM; Taniguchi H; Yuda S; Toyoda K; Yamauchi N; Fukuhara S; Munakata W; Kobayashi Y; Kurihara H; Izutsu K; Tobinai K
    Asia Pac J Clin Oncol; 2020 Jun; 16(3):108-114. PubMed ID: 31802636
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Staging, response to therapy, and restaging of lymphomas with 18F-FDG PET.
    Altamirano J; Esparza JR; de la Garza Salazar J; Calvo PS; Vera SR; Chalapud Revelo JR; Estrada G
    Arch Med Res; 2008 Jan; 39(1):69-77. PubMed ID: 18067998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current Role of Functional Imaging in the Management of Lymphoma.
    Cheson BD; Meignan M
    Curr Oncol Rep; 2021 Nov; 23(12):144. PubMed ID: 34735647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biopsy versus FDG PET/CT in the initial evaluation of bone marrow involvement in pediatric lymphoma patients.
    Cheng G; Chen W; Chamroonrat W; Torigian DA; Zhuang H; Alavi A
    Eur J Nucl Med Mol Imaging; 2011 Aug; 38(8):1469-76. PubMed ID: 21505896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fluorine-18 fluorodeoxyglucose PET-CT for extranodal staging of non-Hodgkin and Hodgkin lymphoma.
    Ömür Ö; Baran Y; Oral A; Ceylan Y
    Diagn Interv Radiol; 2014; 20(2):185-92. PubMed ID: 24412817
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Baseline and ongoing PET-derived factors predict detrimental effect or potential utility of 18F-FDG PET/CT (FDG-PET/CT) performed for surveillance in asymptomatic lymphoma patients in first remission.
    Morbelli S; Capitanio S; De Carli F; Bongioanni F; De Astis E; Miglino M; Verardi MT; Buschiazzo A; Fiz F; Marini C; Pomposelli E; Sambuceti G
    Eur J Nucl Med Mol Imaging; 2016 Feb; 43(2):232-239. PubMed ID: 26283504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 161.